Volume 3, Issue 12
Editorialp. 1097
What does the future hold for uveal melanoma, a historically untreatable disease?
Author(s): Alexander N Shoushtari , Richard D Carvajal
Editorialp. 1101
A close look at trachoma control and the challenges that district programs pose
Author(s): Sheila West
Editorialp. 1105
Reassessment of the dysplastic nevus concept in the 21st century:a proposal for a two-tiered system of classification
Author(s): Hebah Aboul-Fotouh, Lauren A Baker, Michelle Lucero Jackson ,Clay J Cockerell
News and Viewsp. 1109
New evidence supports tandem treatment in some ovarian cancers
Research Updatep. 1113
Developing a consortium for ALS clinical research: the Canadian ALS Research Network
Author(s): Lorne Zinman, Angela Genge,Denise A Figlewicz
Perspectivep. 1119
Beyond Jadad: some essential features in trial quality
Author(s): Sunny Y Alperson ,Vance W Berger
Review Articlep. 1127
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Author(s): Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
Review Articlep. 1139
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Author(s): Paolo Spagnolo,Fabrizio Luppi
Review Articlep. 1147
Surrogate end points: when should they be used?
Author(s): Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
Review Articlep. 1157
Adverse event monitoring in oncology clinical trials
Author(s): Jeffery S Russell , A Dimitrios Colevas
Review: Clinical Trail Outcomesp. 1167
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Author(s): Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomesp. 1179
Macrolide therapy in cystic fibrosis: new developments in clinical use
Author(s): K Frayman,P Robinson
Review: Clinical Trail Outcomesp. 1187
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Author(s): Roberto Lorenzetti, Cosimo Prantera
Acknowledgementsp. 1195
